New Guided VCTE™ technology will increase efficiency, automation and standardization to make liver scanning seamless for all healthcare providersWALTHAM, Mass., Feb. 26, 2024 /PRNewswire/ -- More than 100 million people in the U.S. are affected by some form of liver disease, but only 4.5 million adults have been diagnosed with the condition.

新的引导式VCTE™技术将提高效率、自动化和标准化，使所有医疗保健提供者的肝脏扫描无缝进行。马萨诸塞州斯沃尔瑟姆，2024年2月26日/PRNewswire/——美国有一亿多人受到某种形式的肝脏疾病的影响，但只有450万成年人被诊断出患有这种疾病。

Responding to the dire need for enhanced liver health management, Echosens, the leader in liver health, introduces its new Guided Vibration-Controlled Transient Elastography (VCTE)™ technology, available only on new FibroScan® systems. An essential tool in the battle against liver disease, this next-gen FibroScan launch meets the urgent need for precise, efficient, and non-invasive liver assessment, delivering on the needs of healthcare professionals at the forefront of patient care..

为了应对增强肝脏健康管理的迫切需求，肝脏健康领域的领导者Echosens推出了新的引导振动控制瞬态弹性成像（VCTE）™技术，该技术仅在新的FibroScan®系统上可用。作为对抗肝病的重要工具，下一代FibroScan的推出满足了对精确，高效和无创肝脏评估的迫切需求，满足了处于患者护理前沿的医疗保健专业人员的需求。。

Continue Reading

继续阅读

Echosens introduces next generation FibroScan®: Guided VCTE™

Echosens推出下一代FibroScan®：引导式VCTE™

'Given the significant growth in the at-risk patient population, now at 1 in 10 worldwide, it's critical that we increase screening rates to help prevent a devastating increase in liver disease diagnoses,' said Jon Gingrich, CEO of Echosens North America. 'We've designed the Guided VCTE technology to make non-invasive scans even faster for all patients.

Echosens北美公司首席执行官乔恩·金里奇（JonGingrich）说：“鉴于高危患者人数的大幅增长，目前全球患病率为十分之一，因此我们必须提高筛查率，以帮助防止肝病诊断的毁灭性增长。”我们设计了引导式VCTE技术，可以更快地对所有患者进行无创扫描。

This innovation elevates liver care standards, assuring top-tier disease assessment for all patients, including obese patients, where assessments were previously limited.'.

这项创新提高了肝脏护理标准，确保了所有患者（包括肥胖患者）的顶级疾病评估，这些患者以前的评估是有限的。”。

'Our mission is to make liver assessment far more accessible, and we believe arming physicians with fast, easy and accurate technology is exactly the kind of breakthrough needed to accelerate widespread availability. This new technology is needed to help combat the rise in metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatohepatitis (MASH), especially in the United States,' continued Gingrich..

“我们的使命是使肝脏评估更容易获得，我们相信用快速，简单和准确的技术武装医生正是加速普及所需的突破。金里奇继续说道：“这项新技术有助于对抗代谢功能障碍相关脂肪性肝病（MAFLD）和代谢功能障碍相关脂肪性肝炎（MASH）的上升，尤其是在美国。”。。

Guided VCTE leverages Echosens' diagnostic expertise, providing precise liver stiffness measurements, a critical fibrosis marker. Healthcare professionals can use this sophisticated, user-friendly technology for rapid, non-invasive evaluations across varied patient demographics, significantly improving diagnostic speed and workflow.Patients benefit from quicker and more efficient evaluations, reducing anxiety and discomfort.

引导VCTE利用Echosens的诊断专业知识，提供精确的肝硬度测量，这是一种关键的纤维化标志物。医疗保健专业人员可以使用这种复杂、用户友好的技术对不同的患者人口进行快速、无创的评估，从而大大提高诊断速度和工作流程。患者受益于更快更有效的评估，减少焦虑和不适。

Immediate results also lead to more productive consultations at the point of care, minimizing decision-making and treatment initiation delays.Dr. Tejas Joshi, Director of Liver Diseases at Marshall Health, emphasizes the significance of inclusivity in diagnostics, stating, 'This new technology represents a pivotal innovation in the diagnosis of liver disease, offering unparalleled ease and efficiency across the board, with a noteworthy emphasis on its capability to quickly and accurately scan patients with obesity.

即时结果还可以在护理点进行更有成效的咨询，最大程度地减少决策和治疗开始延迟。马歇尔健康（Marshall Health）肝病主管特贾斯·乔希（Tejas Joshi）博士强调了包容性在诊断中的重要性，他说：“这项新技术代表了肝病诊断的关键创新，提供了无与伦比的简便性和效率，值得注意的是它能够快速准确地扫描肥胖患者。

This feature is critical because it ensures diagnostic precision for chronic liver conditions in a patient population that has historically been challenging to assess, thereby driving better health outcomes and boosting our clinical operations' productivity.'Key features of Guided VCTE include:.

这一功能至关重要，因为它可以确保对历史上一直难以评估的患者人群中慢性肝病的诊断准确性，从而推动更好的健康结果，提高我们临床操作的“生产力”引导式VCTE的主要功能包括：。

Increased efficiency: Taking only four minutes for a full scan, the rapid and efficient nature of Guided VCTE makes it an ideal solution for busy healthcare environments, improving workflow and increasing accessibility to liver health assessments.

提高效率：全扫描只需四分钟，引导式VCTE的快速高效特性使其成为繁忙医疗环境的理想解决方案，改进了工作流程，增加了肝脏健康评估的可访问性。

Improved guidance: Guided VCTE introduces two new visual indicators – one for liver stiffness and one for CAP™ – to aid the operator in quickly identifying the optimal measurement location.

改进的指导：引导式VCTE引入了两个新的视觉指示器-一个用于肝脏硬度，一个用于CAP™-以帮助操作员快速识别最佳测量位置。

Simplified scanning: A refreshed, easily navigable new user interface enables a streamlined workflow and learning curve for all operators. A new efficiency feature, AutoScan, also allows operators to capture ten valid measurements through a single click, increasing efficiency without compromising quality..

简化扫描：一个更新、易于导航的新用户界面为所有操作员提供了简化的工作流程和学习曲线。一个新的效率功能AutoScan还允许操作员通过一次点击捕获十个有效的测量值，从而提高效率而不影响质量。。

Guided VCTE is the latest in Echosens' continuous product innovation and evolution. As the global leader in liver health, Echosens is committed to empowering healthcare professionals with the gold standard non-invasive solution for the comprehensive management of liver health. This evolution signifies a leap forward in simplifying diagnosis and disease management – making liver assessments more accessible and seamlessly integrated in practices than ever before. For more information on Echosens' liver health solutions, visit echosens.com.About EchosensPioneer in its field, Echosens, significantly changed the practice of liver assessment with FibroScan®, the non-invasive solution for comprehensive management of liver health.

Guided VCTE是Echosens持续产品创新和发展的最新产品。作为肝脏健康领域的全球领导者，Echosens致力于为医疗保健专业人员提供黄金标准的无创解决方案，以全面管理肝脏健康。这一演变标志着在简化诊断和疾病管理方面取得了飞跃，使肝脏评估比以往任何时候都更容易获得并无缝整合到实践中。有关Echosens肝脏健康解决方案的更多信息，请访问Echosens.com.About Echosens Pioneer in its field，Echosens，它极大地改变了FibroScan®肝脏评估的实践，FibroScan®是肝脏健康综合管理的非侵入性解决方案。

FibroScan® is recognized worldwide and validated by over 4,200 peer-reviewed publications and 180+ international guidelines. Echosens has made FibroScan® available in over 127 countries, enabling millions of liver examinations worldwide. https://www.echosens.com/SOURCE Echosens.

FibroScan®在全球范围内得到认可，并得到4200多份同行评审出版物和180多份国际指南的验证。Echosens已在127多个国家提供FibroScan®，可在全球范围内进行数百万次肝脏检查。https://www.echosens.com/SOURCE回声传感器。